Blog

• 
• 
• 
• 

Researchers at Vanderbilt University Medical Center and Washington University School of Medicine in St. Louis have isolated a human monoclonal antibody that in a mouse model “markedly reduced” infection by the Zika virus.

The antibody, called ZIKV-117, also protected the fetus in pregnant mice infected with the virus, the researchers reported today in the journal Nature. Zika is believed to cause microcephaly, unusually small heads, and other congenital malformations in children born to infected women.

CTTC currently has three active innovations that could in the future have an impact on the detection and treatment of heart disease. We are seeking commercialization and licensing partnership for these technologies.

Catheter Having Temperature Controlled Anchor and Related Methods

Assessment of Right Ventricular Function Using Contrast Echocardiography

Getting to a patient’s room or finding the right clinic for an appointment can be stressful, but Vanderbilt University Medical Center (VUMC) leaders believe a mobile app, called WalkWays, as well as a texting tool that provide easily understood, visual directions will help everyone find their way.

Vanderbilt Licensee gets acquired by Agilent Technologies

Vanderbilt team competes at NSF I-CORPS

Harris Computer Corporation announced that it has completed the acquisition of digiChart Inc. digiChart is a Vanderbilt start-up and is a provider of electronic medical records (EMR) and practice management solutions for Obstetricians and Gynecologists (OB/GYN) practices in the United States.

digiChart’s innovative Software as a Service (SaaS) solutions complement  Harris’ existing healthcare information technology (“HCIT”) portfolio.  Harris will continue to develop, sell, implement and support the digiChart products from its headquarters in Nashville, TN.

IQuity, Inc. was formed by a group of talented Vanderbilt scientists and experienced business people committed to innovation in specialty diagnostic technologies. The company’s mission is to help providers diagnose faster, treat sooner and, ultimately, improve the lives of patients suffering from autoimmune diseases.

Research in the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) aimed at developing innovative new treatments for schizophrenia just received a powerful assist from The William K. Warren Foundation.

The Tulsa, Oklahoma-based foundation announced it will increase its support by another $1 million, as VCNDD’s game-changing schizophrenia program approaches the point at which candidate drugs will be selected for testing in clinical trials. Two previous awards from the foundation have totaled $7.25 million since 2014.